This phase III trial is trying to determine if extended post-radiation chemotherapy will improve survival outcomes in patients with newly diagnosed glioblastoma.
This trial is treating patients with glioblastoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase III Trial of Extended Temozolomide in Newly Diagnosed Glioblastoma
Other Non-Commercial Sponsor
Walter and Eliza Hall Institute
This trial is comparing two standards of care - 6 versus 12 cycles of post radiation temozolomide. Patients in Arm A of the trial will undergo observation with standard clinical and radiological follow up. Patients in Arm B will receive an additional 6 cycles of post-radiation temozolomide (orally) followed by observation with standard clinical and radiological follow up.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More